Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Biotransformation of Rosamicin Antibiotic into 10,11-Dihydrorosamicin with Enhanced In Vitro Antibacterial Activity Against MRSA

  • Nguyen, Lan Huong (Department of Pharmaceutical Engineering, SunMoon University) ;
  • Nguyen, Huu Hoang (Department of Pharmaceutical Engineering, SunMoon University) ;
  • Shrestha, Anil (Department of Pharmaceutical Engineering, SunMoon University) ;
  • Sohng, Jae Kyung (Department of Pharmaceutical Engineering, SunMoon University) ;
  • Yoon, Yeo Joon (Department of Chemistry and Nano Science, Ewha Womans University) ;
  • Park, Je Won (Department of Pharmaceutical Engineering, SunMoon University)
  • Received : 2013.06.24
  • Accepted : 2013.09.23
  • Published : 2014.01.28
Download PDF
⟨ Previous Next ⟩

Abstract

A biotransformation approach using microbes as biocatalysts can be an efficient tool for the targeted modification of existing antibiotic chemical scaffolds to create previously uncharacterized therapeutic agents. By employing a recombinant Streptomyces venezuelae strain as a microbial catalyst, a reduced macrolide, 10,11-dihydrorosamicin, was created from rosamicin macrolide. Its chemical structure was spectroscopically elucidated, and the new rosamicin analog showed 2-4-fold higher antibacterial activity against two strains of methicillin-resistant Staphylococcus aureus compared with its parent rosamicin. This kind of biocatalytic approach is able to expand existing antibiotic entities and can also provide more diverse therapeutic resources.

Keywords

References

  1. Anzai Y, Iizaka Y, Li W, Idemoto N, Tsukada S, Koike K, et al. 2009. Production of rosamicin derivatives in Micromonospora rosaria by introduction of D-mycinose biosynthetic gene with PhiC31-derived integration vector pSET152. J. Ind. Microbiol. Biotechnol. 36: 1013-1021. https://doi.org/10.1007/s10295-009-0579-y
  2. Anzai Y, Sakai A, Li W, Iizaka Y, Koike K, Kinoshita K, Kato F. 2010. Isolation and characterization of 23-Omycinosyl- 20-dihydro-rosamicin: a new rosamicin analogue derived from engineered Micromonospora rosaria. J. Antibiot. 63: 325-328. https://doi.org/10.1038/ja.2010.38
  3. Baumueller A, Hoyme U, Madsen PO. 1977. Rosamicin - a new drug for the treatment of bacterial prostatitis. Antimicrob. Agents Chemother. 12: 240-242. https://doi.org/10.1128/AAC.12.2.240
  4. Fischbach MA, Walsh CT. 2009. Antibiotics for emerging pathogens. Science 325: 1089-1093. https://doi.org/10.1126/science.1176667
  5. Iizaka Y, Higashi N, Ishida M, Oiwa R, Ichikawa Y, Takeda M, et al. 2013. Function of cytochrome P450 enzymes RosC and RosD in the biosynthesis of rosamicin macrolide antibiotic produced by Micromonospora rosaria. Antimicrob. Agents Chemother. 57: 1529-1531. https://doi.org/10.1128/AAC.02092-12
  6. Lee BK, Puar MS, Patel M, Bartner P, Lotvin J, Munayyer H, Waitz JA. 1983. Multistep bioconversion of 20-deoxo-20- dihydro-12,13-deepoxy-12,13-dehydrorosaranolide to 22-hydroxy- 23-O-mycinosyl-20-deoxo-20-dihydro-12,13-deepoxy-rosaramicin. J. Antibiot. 36: 742-744. https://doi.org/10.7164/antibiotics.36.742
  7. Park JW, Oh HS, Jung WS, Park SR, Han AR, Ban YH, et al. 2008. Exploiting the natural metabolic diversity of Streptomyces venezuelae to generate unusual reduced macrolides. Chem. Commun. 44: 5782-5784.
  8. Park JW, Park SR, Han AR, Ban YH, Yoo YJ, Kim EJ, et al. 2011. Generation of reduced macrolide analogs by regiospecific biotransformation. J. Antibiot. 64: 155-157. https://doi.org/10.1038/ja.2010.143
  9. Park JW, Park SR, Han AR, Ban YH, Yoo YJ, Kim EJ, et al. 2011. Microbial transformation of trichostatin A to 2,3- dihydrotrichostatin A. J. Nat. Prod. 74: 1272-1274. https://doi.org/10.1021/np1006718
  10. Park JW, Park SR, Nepal KK, Han AR, Ban YH, Yoo YJ, et al. 2011. Discovery of parallel pathways of kanamycin biosynthesis allows antibiotic manipulation. Nat. Chem. Biol. 7: 843-852. https://doi.org/10.1038/nchembio.671
  11. Sadakane N, Tanaka Y, Omura S. 1982. Hybrid biosynthesis of derivatives of protylonolide and M-4365 by macrolideproducing microorganisms. J. Antibiot. 35: 680-687. https://doi.org/10.7164/antibiotics.35.680
  12. Saleem M, Nazir M, Ali MS, Hussain H, Lee YS, Riaz N, Jabbar A. 2010. Antimicrobial natural products: an update on future antibiotic drug candidates. Nat. Prod. Rep. 27: 238-254. https://doi.org/10.1039/b916096e
  13. Wagman GH, Waitz JA, Marquez J, Murawaski A, Oden EM, Testa RT, Weinstein MJ. 1972. A new Micromonosporaproduced macrolide antibiotic, rosamicin. J. Antibiot. 25: 641-646. https://doi.org/10.7164/antibiotics.25.641
  14. Zhou J, Ogle JW, Fan Y, Banphavichit V, Zhu Y, Burgess K. 2007. Asymmetric hydrogenation routes to deoxypolyketide chirons. Chemistry 13: 7162-7170. https://doi.org/10.1002/chem.200700390

Cited by

  1. Recent progress on the development of antibiotics from the genus Micromonospora vol.21, pp.2, 2014, https://doi.org/10.1007/s12257-015-0574-2
  2. Engineering actinomycetes for biosynthesis of macrolactone polyketides vol.18, pp.None, 2019, https://doi.org/10.1186/s12934-019-1184-z